"Growth hormone peptides" are usually discussed as a single category online. Medically and legally they are not. One compound in this family — tesamorelin — is an FDA-approved medicine with randomised phase 3 trials behind it. The others commonly sold, ipamorelin and sermorelin, are research compounds with narrower and older evidence. Treating them as interchangeable obscures the only question that matters: what has actually been tested in humans, under regulatory oversight, and for which condition?

Growth hormone (GH) release from the pituitary is controlled by two hypothalamic signals: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which restrains it. A third signal acts through the ghrelin receptor (GHS-R1a), the target of the "growth hormone secretagogue" class. GH in turn drives hepatic production of IGF-1, which mediates many of its effects on tissue. Every compound discussed here works by nudging this axis; none of them is growth hormone itself.

Tesamorelin (brand name Egrifta) is a GHRH analogue approved by the FDA in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — a specific metabolic complication of HIV and its treatment, not a general weight-loss or anti-ageing indication.

The evidence is genuinely phase 3. Falutz and colleagues reported in the New England Journal of Medicine (2007) a randomised, placebo-controlled trial in HIV patients with abdominal fat accumulation, in which tesamorelin reduced visceral adipose tissue compared with placebo, with increases in IGF-1 and the expected class effects on glucose metabolism. A pooled analysis of two multicentre phase 3 trials with safety extension data (JCEM, 2010) confirmed the visceral-fat reduction and documented adverse events — arthralgia, oedema, injection-site reactions — consistent with GH-axis stimulation.

The prescribing information (DailyMed) carries the limits plainly: tesamorelin is not indicated for weight loss, its long-term cardiovascular effects are not established, and treatment effects on visceral fat reverse after discontinuation. This is what "approved" looks like — a defined population, a measured effect, and stated boundaries.

One member of this class has completed the full evidence pathway: a defined indication, randomised trials, a regulator-reviewed label. The rest have not.

Ipamorelin was characterised by Raun and colleagues at Novo Nordisk in 1998 as "the first selective growth hormone secretagogue" — a pentapeptide acting at the ghrelin/GHS receptor that released GH in vitro and in vivo without meaningfully raising ACTH, cortisol or prolactin, the off-target hormone spillover seen with earlier secretagogues. That selectivity paper, in the European Journal of Endocrinology , remains the reference point for the compound.

What followed is instructive: ipamorelin never became a medicine. Development did not produce an approved indication, and the published human record remains limited. Its current availability is as a research chemical. Animal and mechanistic data describing GH release cannot answer the questions that matter clinically — sustained efficacy, long-term safety, dosing — because those studies were never completed in humans.

Sermorelin is a synthetic fragment of GHRH (the 1–29 sequence) that was briefly marketed decades ago for paediatric growth-hormone deficiency diagnostics and treatment, and later withdrawn from the U.S. market — for commercial reasons, not as a modern approval for adults. The literature on it is real but dated: studies in the 1990s (Vittone 1997; Khorram 1997) showed that nightly GHRH(1-29) administration could raise GH and IGF-1 in healthy elderly adults, and a 2006 review by Walker argued the case for its use in adult GH insufficiency.

These studies establish that the axis responds in older adults — not that treatment produces clinical benefit. No large modern trial has shown that sermorelin improves strength, body composition or healthspan outcomes in healthy ageing people, and it is not approved for any such use. Claims of "anti-ageing" effects go well beyond the published record.

Compound Class Regulatory status Human evidence

Tesamorelin GHRH analogue FDA-approved (2010) for HIV lipodystrophy Randomised phase 3 trials (NEJM 2007; JCEM 2010)

Ipamorelin Ghrelin-receptor secretagogue Not approved anywhere Preclinical characterisation; limited human data

Sermorelin GHRH(1-29) fragment Former paediatric product; no current general approval Small, dated studies in elderly adults; no modern outcome trials

Stimulating the GH axis is not neutral. The phase 3 tesamorelin programme documented glucose-metabolism effects, and the label warns about fluid retention, arthralgia and injection reactions. For unapproved compounds, no equivalent safety database exists at all: not because they are proven safe, but because the studies that would detect harm have not been run. Sustained elevation of IGF-1 is itself a biological exposure whose long-term consequences in healthy people are unknown.

Because human dosing and safety ranges are not established for the unapproved compounds, this publication does not provide dosing information for them.

The growth-hormone secretagogue family illustrates the whole evidence ladder in one place. Tesamorelin stands on randomised trials and a regulator-reviewed label for one narrow indication. Ipamorelin stands on elegant preclinical pharmacology that was never followed through in humans. Sermorelin stands on dated, small studies that show a hormonal response without demonstrated clinical benefit. The distance between "raises GH in a study" and "helps a person" is the distance between these compounds — and it is exactly the distance that marketing language exists to hide.

The sources above are the primary material for this review: the NEJM and JCEM tesamorelin trials and the current prescribing information, the original ipamorelin characterisation, and the 1990s GHRH studies and 2006 sermorelin review for the older literature.